Management of Cannabis Hyperemesis Syndrome
The cornerstone of cannabis hyperemesis syndrome (CHS) management is complete cannabis cessation, which is the only definitive cure; for acute symptom control, use topical capsaicin or haloperidol as first-line agents, while avoiding opioids entirely due to worsening of nausea and high addiction risk. 1
Acute Management (Emergency Department/Immediate Care)
First-Line Therapies
When patients present with acute CHS symptoms, your immediate approach should prioritize:
- Topical capsaicin (0.1% cream): Apply to the abdomen with close monitoring. This works by activating transient receptor potential vanilloid type 1 receptors 1
- Haloperidol: Effective dopamine antagonist for acute symptom control 1, 2, 3
- Droperidol: Alternative dopamine antagonist 2
Second-Line Options
If first-line agents are insufficient or contraindicated:
- Benzodiazepines 1, 3
- Promethazine 1
- Olanzapine 1
- Ondansetron 1 (though conventional antiemetics often fail in CHS 3)
- Metoclopramide 2
Critical Pitfall: What NOT to Use
Avoid opioids completely - they worsen nausea and carry high addiction risk in this population 1. Opioids and benzodiazepines should not be first-line therapy 2.
Emergency Department Considerations
Before diagnosing CHS, you must exclude life-threatening conditions including acute abdomen, bowel obstruction, mesenteric ischemia, pancreatitis, and myocardial infarction 1. The evidence emphasizes this is a diagnosis of exclusion in the acute setting.
Long-Term Management (Definitive Treatment)
The mainstay of long-term therapy is cannabis cessation counseling combined with amitriptyline 1:
Amitriptyline Dosing Protocol
- Start: 25 mg at bedtime
- Titrate: Increase weekly by increments
- Target: 75-100 mg at bedtime (minimal effective dose) 1
Psychosocial Support
Combining evidence-based psychosocial interventions with pharmacology is necessary for successful long-term management 1. Co-management with psychology or psychiatry is helpful for patients with:
- Lack of response to standard therapies
- Extensive psychiatric comorbidity
- Anxiety and depression (very common associated conditions) 1
Diagnostic Confirmation
Before initiating treatment, confirm the diagnosis using these criteria 1:
1. Clinical Features:
- Stereotypical episodic vomiting resembling cyclic vomiting syndrome
- Frequency: 3 or more episodes annually
2. Cannabis Use Patterns:
- Duration: More than 1 year of use before symptom onset
- Frequency: More than 4 times per week on average
3. Cannabis Cessation:
- Resolution of symptoms after at least 6 months of abstinence, OR
- Resolution equal to the total duration of 3 typical vomiting cycles
Supportive Finding: Hot water bathing behavior (reported in 71% of CHS patients) 1, though this is not pathognomonic as it also occurs in cyclic vomiting syndrome 1.
Outpatient Differential Diagnosis
After excluding structural abnormalities, consider:
- Rumination syndrome
- Gastroparesis
- Cyclic vomiting syndrome (non-cannabis related)
- Pregnancy
- Migraine
- Functional chronic nausea and vomiting syndrome 1
Evidence Limitations and Clinical Reality
The evidence for CHS treatment is limited to case series and small clinical trials 1. Despite this, the 2024 AGA guidelines provide the most comprehensive and recent framework available.
Important caveat: Recidivism rates are high - over 40% of patients may stop treatments over time, but many return to cannabis use 1. Many patients remain uncertain about the role of cannabis despite recurrent episodes and diagnosis, often attributing symptoms to food, alcohol, stress, or other GI disorders 1.
Unvalidated Strategies to Avoid
Do not recommend these commonly suggested but scientifically unvalidated approaches:
- Switching to lower THC/higher CBD formulations
- Using edible forms instead of smoking
- Avoiding THC concentrates 1
The only validated long-term solution remains complete cannabis cessation 1, 3.